A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of Pergoveris (follitropin alfa and lutropin alfa) and GONAL-f (follitropin alfa) for multifollicular development as part of an assisted reproductive technology treatment cycle in poor ovarian responders, as defined by the European Society of Human Reproduction and Embryology criteria

Trial Profile

A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of Pergoveris (follitropin alfa and lutropin alfa) and GONAL-f (follitropin alfa) for multifollicular development as part of an assisted reproductive technology treatment cycle in poor ovarian responders, as defined by the European Society of Human Reproduction and Embryology criteria

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Follitropin alfa (Primary) ; Follitropin alfa/lutropin alfa (Primary) ; Choriogonadotropin alfa
  • Indications Female infertility
  • Focus Registrational; Therapeutic Use
  • Acronyms ESPART
  • Sponsors Merck KGaA
  • Most Recent Events

    • 08 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 26 Jun 2015 Planned End Date changed from 1 May 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
    • 26 Jun 2015 Planned primary completion date changed from 1 May 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top